SPAC Proposes $600M Alpha AI Biotech Deal; Investor Adds $250K Convertible Funding
DMII is trading near its 52-week low of $9.86 (3.9% above the low) on light trading volume (0.1× avg).
Summary
Drugs Made In America Acquisition II disclosed a nonbinding proposal to buy Alpha AI Biotech at a $600 million pre-money valuation in stock, with up to 30 million earn-out shares, and said its investor funded another $250,000 of convertible notes, now consolidated into a $700,000 note due June 2027.
Key Events · M&A and Partnerships · DMII
-
Alpha AI Biotech Deal Proposed
The nonbinding proposal values Alpha at $600 million pre-money, paid in 60,000,000 ordinary shares at $10.00 per share, plus up to 30,000,000 earn-out shares in two equal tranches tied to $12.50 and $15.00 thresholds over the 24 months after closing.
-
No Definitive Agreement Signed
Except for confidentiality, the standstill and the funding acknowledgment, the proposal is nonbinding, and it remains subject to due diligence, audited financials, definitive agreements and board, shareholder and regulatory approvals.
-
30-Day Standstill Through December 3
A limited standstill expiring on or about December 3, 2026 was approved by the board; it restricts only consummation of a competing transaction, not evaluation or negotiation of alternatives.
-
Convertible Funding Reaches $700,000
The Investor funded a further $250,000 on November 6, 2026, so $700,000 of the $1,400,000 commitment is funded and $700,000 remains available; the Bridge Note, Second Note and new installment consolidate into one $700,000 note maturing June 30, 2027.
Analysis · DMII · Real Estate & Construction
Here is the first public look at what this blank-check company intends to buy: Alpha AI Biotech Group, at a $600 million pre-money valuation, paid in 60 million shares at $10.00 plus up to 30 million earn-out shares if the stock reaches $12.50 and $15.00 within two years of closing. Nothing is signed. Apart from confidentiality, a 30-day standstill expiring around December 3, 2026, and the funding acknowledgment, the proposal is nonbinding, so the deal can still change or collapse. Alongside it, the Israeli investor already backing the company put in another $250,000, bringing funded convertible notes to $700,000 of the $1,400,000 commitment, and the three notes are being rolled into one $700,000 note maturing June 30, 2027 instead of December 2026. That conversion feature matters: at a 35% discount to market at conversion, the note converts into meaningfully more shares than its face value implies. The governance wrinkle is that the Investor's CEO, Alon Izidor Tal, also sits on Alpha's board and accepted the proposal for Alpha, a conflict the all-independent board says it was aware of.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DMII was trading at $10.25 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $652.6M. The 52-week trading range was $9.86 to $10.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.